NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 96 filers reported holding NGM BIOPHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.75 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,843 | -58.4% | 11,069 | +0.7% | 0.00% | – |
| Q2 2023 | $28,482 | -33.2% | 10,997 | +5.3% | 0.00% | – |
| Q1 2023 | $42,624 | -29.0% | 10,447 | -12.7% | 0.00% | – |
| Q4 2022 | $60,044 | -58.6% | 11,961 | +7.4% | 0.00% | -100.0% |
| Q3 2022 | $145,000 | +6.6% | 11,138 | +5.3% | 0.00% | – |
| Q2 2022 | $136,000 | -36.2% | 10,576 | -24.2% | 0.00% | – |
| Q1 2022 | $213,000 | -32.6% | 13,949 | -21.8% | 0.00% | -100.0% |
| Q4 2021 | $316,000 | -26.9% | 17,830 | -13.3% | 0.00% | 0.0% |
| Q3 2021 | $432,000 | -0.5% | 20,562 | -6.6% | 0.00% | 0.0% |
| Q2 2021 | $434,000 | -12.5% | 22,012 | +29.1% | 0.00% | -50.0% |
| Q1 2021 | $496,000 | +2.7% | 17,050 | +7.0% | 0.00% | 0.0% |
| Q4 2020 | $483,000 | +116.6% | 15,931 | +13.7% | 0.00% | +100.0% |
| Q3 2020 | $223,000 | -19.8% | 14,013 | -0.5% | 0.00% | 0.0% |
| Q2 2020 | $278,000 | +112.2% | 14,081 | +32.7% | 0.00% | 0.0% |
| Q1 2020 | $131,000 | -60.1% | 10,611 | -40.1% | 0.00% | -50.0% |
| Q4 2019 | $328,000 | – | 17,723 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RHO CAPITAL PARTNERS INC | 3,766,666 | $79,175,000 | 44.14% |
| Ponoi II Management, LLC | 1,298,908 | $27,303,000 | 40.46% |
| Column Group LLC | 15,396,116 | $323,626,000 | 36.81% |
| Ponoi Management, LLC | 1,298,908 | $27,303,000 | 24.24% |
| Euclidean Capital LLC | 832,274 | $17,494,000 | 8.50% |
| StepStone Group LP | 1,573,357 | $33,072,000 | 2.14% |
| Octagon Capital Advisors LP | 200,000 | $4,204,000 | 1.04% |
| Redmile Group, LLC | 2,505,118 | $52,658,000 | 0.92% |
| BVF INC/IL | 955,000 | $20,074,000 | 0.78% |
| Boxer Capital, LLC | 500,000 | $10,510,000 | 0.37% |